MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.imlet.2020.04.005

Медицинская библиотека · Immunology letters · 2020

Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.

Fallah-Mehrjardi Keyvan, Mirzaei Hamid Reza, Masoumi Elham, Jafarzadeh Leila, Rostamian Hosein, Khakpoor-Koosheh Mohammad, Alishah Khadijeh, Noorbakhsh Farshid, Hadjati Jamshid

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

In spite of impressive results in the treatment of acute lymphoblastic B cell leukemia (B-ALL) with chimeric antigen receptor (CAR) T cells, the clinical outcome of some hematological cancers like follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) has not been very promising likely due to immunosuppressive networks within tumor microenvironment. Hypoxia in the microenvironment of hematological malignancies and consequently generation of adenosine molecule is appeared to be correlated with immunosuppression, tumor progression, and relapse. Herein, we hypothesized that whether pharmacological targeting of adenosine 2a receptor (A2aR) can enhance antitumor activity of anti-CD19 CAR T cells in vitro. Prior to functional assays, A2aR expression was assessed in CAR-expressing T cells. Our results showed that A2aR was not only up-regulated in the fully human anti-CD19 CAR T cells (hereafter referred to as huCAR19 T cells) but also was further overexpressed following re-stimulation with target cells. Although pharmacological inhibition of A2aR could significantly increase proliferation capacity and cytokine production of huCAR19 T cells following treatment with an adenosine analog, cytotoxic activity of huCAR19 T cells was not significantly improved. Considering A2aR overexpression in huCAR19 T cells in the tumor microenvironment, our results indicated that pharmacological targeting of A2aR could not only improve huCAR19 T cells functionality in a hostile tumor microenvironment but also could have a therapeutic advantage, and sought to assess the possibility in a pre-clinical setting.

Для цитирования: Fallah-Mehrjardi Keyvan, Mirzaei Hamid Reza, Masoumi Elham, Jafarzadeh Leila, Rostamian Hosein, Khakpoor-Koosheh Mohammad, Alishah Khadijeh, Noorbakhsh Farshid, Hadjati Jamshid. Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.. Immunology letters. 2020. DOI: 10.1016/j.imlet.2020.04.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.